Opdualag (Nivolumab and Relatlimab) Drug Insight and Market Forecast - 2035

“Opdualag (nivolumab and relatlimab) Drug Insight and Market Forecast - 2035” report provides comprehensive insights about Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies in the 7MM. A detailed picture of the Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2035 is provided in this report along with a detailed description of the Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies . The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Opdualag (nivolumab and relatlimab) market forecast, analysis for LAG-3 Next-generation Immunotherapies in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in LAG-3 Next-generation Immunotherapies.

Drug Summary

Relatlimab is a LAG-3-blocking antibody that binds to LAG-3 on T cells, restoring the effector function of exhausted T cells. The combination of nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) results in increased T-cell activation compared to the activity of either antibody alone. Relatlimab (in combination with nivolumab) is the first LAG-3-blocking antibody to demonstrate a benefit in a Phase III study. It is the third checkpoint inhibitor (along with anti-PD-1 and anti-CTLA-4) for Bristol Myers Squibb. When relatlimab binds to LAG-3 on T cells, this process essentially releases those brakes and stimulates T cells to attack cancer cells. This way, the immune system is again able to work as intended against cancer, reducing tumor growth.

In September 2022, the European Commission (EC) approved the fixed-dose combination of Opdualag (nivolumab and relatlimab) for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 and older with tumor cell PD-L1 expression < 1%.

In March 2022, the US Food and Drug Administration approved the first LAG-3-blocking antibody combination, Opdualag (nivolumab and relatlimab), as a treatment for patients with unresectable or metastatic melanoma.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Opdualag (nivolumab and relatlimab) description, mechanism of action, dosage and administration, research and development activities in LAG-3 Next-generation Immunotherapies.
• Elaborated details on Opdualag (nivolumab and relatlimab) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Opdualag (nivolumab and relatlimab) research and development activity in LAG-3 Next-generation Immunotherapies in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Opdualag (nivolumab and relatlimab).
• The report contains forecasted sales of Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies till 2035.
• Comprehensive coverage of the late-stage emerging therapies for LAG-3 Next-generation Immunotherapies.
• The report also features the SWOT analysis with analyst views for Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Opdualag (nivolumab and relatlimab) Analytical Perspective

In-depth Opdualag (nivolumab and relatlimab) Market Assessment

This report provides a detailed market assessment of Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2035.

Opdualag (nivolumab and relatlimab) Clinical Assessment

The report provides the clinical trials information of Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for LAG-3 Next-generation Immunotherapies is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Opdualag (nivolumab and relatlimab) dominance.
• Other emerging products for LAG-3 Next-generation Immunotherapies are expected to give tough market competition to Opdualag (nivolumab and relatlimab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies.
• This in-depth analysis of the forecasted sales data from 2022 to 2035 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of Opdualag (nivolumab and relatlimab)?
• What is the clinical trial status of the study related to Opdualag (nivolumab and relatlimab) in LAG-3 Next-generation Immunotherapies and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Opdualag (nivolumab and relatlimab) development?
• What are the key designations that have been granted to Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies?
• What is the forecasted market scenario of Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies?
• What are the forecasted sales of Opdualag (nivolumab and relatlimab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in LAG-3 Next-generation Immunotherapies and how are they giving competition to Opdualag (nivolumab and relatlimab) for LAG-3 Next-generation Immunotherapies?
• Which are the late-stage emerging therapies under development for the treatment of LAG-3 Next-generation Immunotherapies?

This product will be delivered within 2 business days.